Authors


Oscar Chen, MD, MS

Latest:

Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresis

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.


Carl Regillo, MD, FACS, FASRS

Latest:

Key Takeaways on Managing Neovascular AMD and DME

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.



Todd Stein

Latest:

Leaders in academic ophthalmology discuss AI for eye screening

Artificial intelligence in a primary care and clinic settings increases the likelihood of catching diabetic retinopathy in underinsured patients, resulting in increased successful referrals.



Winfried Amoaku, FRCS, FRCOphth, PhD, AFHEA

Latest:

Pearls for managing diabetic retinopathy in pediatric patients

Insulin pumps, digital technology and outcome analyses are useful tools


Victoria Johnson

Latest:

Serious adverse reaction halts gene therapy for diabetic macular edema

Despite setbacks in DME, Adverum Biotechnologies said it will continue to develop ADVM-022 for wet AMD.


Hashem Ghoraba, MD, MSc

Latest:

Ultra-widefield imaging: A critical step in uveitis diagnosis and management

A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.


Adrienne Scott, MD

Latest:

Key Takeaways on Managing Neovascular AMD and DME

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.


Arshad M. Khanani, MD, MA, FASRS

Latest:

Learnings from Real World Evidence of Faricimab in nAMD and DME: Part 2

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.


Veeral Sheth, MD, MBA, FAS, FASRS

Latest:

New VEGF trap for wet AMD takes aim at VEGF-C and VEGF-D

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.



Sunir Garg, MD

Latest:

Intravitreal pegcetacoplan for retinal tissue preservation in patients with GA

Garg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).


David A. Eichenbaum, MD

Latest:

Take-Home Points for the Treatment of AMD and DME

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.



Konstantinos Balaskas, MB BS, MD, FEBO, MRCOPHTH

Latest:

How ophthalmology is pioneering the field of artificial intelligence

Retinal imaging tests are providing material to train and test decision support systems.


Marc Mathias, MD

Latest:

Pediatric ophthalmologists target inherited retinal diseases

New opportunities continue to develop in an evolving landscape.


Peter Wehrwein

Latest:

Case series finds floaters are a common side effect of Syfovre

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.


Peter K. Kaiser, MD

Latest:

VEGF and beyond: therapeutic targeting in retinal vascular disorders

Promoting Tie2 signaling activity may complement inhibition of VEGF in addressing pathology in disease states characterized by angiogenesis, vascular permeability, and inflammation.


Mariya Moosajee, MBBS, BSc, PhD, FRCOphth

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Prethy Rao, MD, MPH

Latest:

Key Takeaways on Managing Neovascular AMD and DME

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.


Lee MacMorris

Latest:

OCT: First 2D image by Adolf Fercher paved the way for today’s imaging technique

In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.



Ajay V. Srivastava, MD, FACC

Latest:

Listening to the heart: Lessons from cardiology in remote monitoring and AI

Rather than speculating in a vacuum about the future of remote monitoring in ophthalmology, it is better to explore how other specialties in medicine adopted and integrated remote monitoring into their care plan frameworks.


Adam M. Katz, MD

Latest:

Dexamethasone rebuttal: Who should perform intravitreal injections?

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.


Sibylle Scholtz, PhD

Latest:

OCT: First 2D image by Adolf Fercher paved the way for today’s imaging technique

In the 30 years since optical coherence tomography was first described, it has become one of the most widely used technologies for imaging the human eye.


Jose Agustin Martinez, MD, FASRS

Latest:

Significance of periphery in diabetic retinopathy diagnosis and management

Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.


Caroline Richards

Latest:

2023: What awaits ophthalmology in the year ahead

As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.


Matthew Roe, MD, MHS

Latest:

Big data: Driving opportunity for real-world evidence

Evidence-based medicine can lead to personalized care, better results for patients


Jayanth Sridhar, MD

Latest:

Practice perspective: Academic retina

A window into the world of academic retina practice today.

© 2024 MJH Life Sciences

All rights reserved.